Featured Research

from universities, journals, and other organizations

Arginine therapy shows promise for sickle cell pain

Date:
September 16, 2013
Source:
Emory Health Sciences
Summary:
Arginine therapy may be a safe and inexpensive treatment for acute pain episodes in patients with sickle cell disease, according to results of a recent clinical study.

The abnormal hemoglobin in sickle cell disease causes red blood cells to distort into a sickle, or crescent shape that often blocks blood flow in small blood vessels, leading to severe pain and organ damage.
Credit: Woodruff Health Sciences Center

Arginine therapy may be a safe and inexpensive treatment for acute pain episodes in patients with sickle cell disease, according to results of a recent clinical study. The study was the first randomized placebo-controlled study to demonstrate benefits of arginine therapy in children with sickle cell disease hospitalized for severe pain.

Related Articles


Sickle cell disease is an inherited condition in which the body makes red blood cells containing abnormal hemoglobin, the protein that carries oxygen from the lungs to other cells in the body. This abnormal hemoglobin (hemoglobin S) causes red blood cells to distort into a sickle, or crescent shape that often blocks blood flow in small blood vessels, leading to severe pain and organ damage.

Arginine is an amino acid found in a normal diet, but is also available as a nutritional supplement. Previous work done by the authors identified an acute arginine deficiency in children during pain episodes, with lowest arginine levels found in children with pain severe enough to require hospitalization. A deficiency of nitric oxide, a potent vasodilator, has been identified in sickle cell disease and may contribute to episodes of blocked vessels and pain. Since arginine is a building block of nitric oxide, researchers hypothesized that arginine could be a beneficial treatment for pain related to sickle cell disease.

Previous research by the authors also found that a single dose of arginine given to patients with sickle cell disease and acute pain episodes resulted in a significant dose-dependent increase in plasma nitric oxide concentration.

Building on that knowledge, the current research study was a randomized, double blind placebo control clinical trial of 38 children with sickle cell disease hospitalized for 56 episodes of pain. The research team discovered a 54 percent reduction in the use of opioid pain medication and significantly lower pain scores at hospital discharge in those treated with arginine over those receiving placebo.

The results were published in the journal Haematologica. First author was Claudia R. Morris, MD, Associate Professor of Pediatrics and Emergency Medicine at Emory University School of Medicine. She conducted the study while in her previous position at Children's Hospital & Research Center Oakland, in Oakland, CA, with Dr. Elliott P. Vichinsky, MD and colleagues.

"Episodes of pain due to vaso-occlusion are the leading cause of hospital admission and emergency room visits and are associated with increased mortality, yet there is no effective therapy targeting the underlying cause," says Morris. "Treatment consists only of symptom relief with pain medicines and hydration. There is an urgent need for new therapies for acute sickle cell pain, and a greater than 50 percent reduction in use of opioid pain medication was a remarkable finding."

The study found no problems with safety in the use of arginine therapy. Although the treatment did not result in a significantly shorter length of stay in the hospital, a trending decrease in hospital stay by 17 hours favored the arginine arm. The researchers believe delivering the study drug as early as possible in the emergency department or clinic may have a greater impact on length of stay, since many patients received their first dose of medication more than 24 hours after presenting the emergency department.

A large, multi-center trial is warranted in order to confirm these observations and test the effects of delivering the therapy sooner, they note in the published paper.


Story Source:

The above story is based on materials provided by Emory Health Sciences. Note: Materials may be edited for content and length.


Journal Reference:

  1. C. R. Morris, F. A. Kuypers, L. Lavrisha, M. Ansari, N. Sweeters, M. Stewart, G. Gildengorin, L. Neumayr, E. P. Vichinsky. A randomized, placebo-controlled trial of arginine therapy for the treatment of children with sickle cell disease hospitalized with vaso-occlusive pain episodes. Haematologica, 2013; 98 (9): 1375 DOI: 10.3324/haematol.2013.086637

Cite This Page:

Emory Health Sciences. "Arginine therapy shows promise for sickle cell pain." ScienceDaily. ScienceDaily, 16 September 2013. <www.sciencedaily.com/releases/2013/09/130916204726.htm>.
Emory Health Sciences. (2013, September 16). Arginine therapy shows promise for sickle cell pain. ScienceDaily. Retrieved October 24, 2014 from www.sciencedaily.com/releases/2013/09/130916204726.htm
Emory Health Sciences. "Arginine therapy shows promise for sickle cell pain." ScienceDaily. www.sciencedaily.com/releases/2013/09/130916204726.htm (accessed October 24, 2014).

Share This



More Health & Medicine News

Friday, October 24, 2014

Featured Research

from universities, journals, and other organizations


Featured Videos

from AP, Reuters, AFP, and other news services

IKEA Desk Converts From Standing to Sitting With One Button

IKEA Desk Converts From Standing to Sitting With One Button

Buzz60 (Oct. 24, 2014) IKEA is out with a new convertible desk that can convert from a sitting desk to a standing one with just the push of a button. Jen Markham explains. Video provided by Buzz60
Powered by NewsLook.com
Ebola Protective Suits Being Made in China

Ebola Protective Suits Being Made in China

AFP (Oct. 24, 2014) A factory in China is busy making Ebola protective suits for healthcare workers and others fighting the spread of the virus. Duration: 00:38 Video provided by AFP
Powered by NewsLook.com
WHO: Millions of Ebola Vaccine Doses by 2015

WHO: Millions of Ebola Vaccine Doses by 2015

AP (Oct. 24, 2014) The World Health Organization said on Friday that millions of doses of two experimental Ebola vaccines could be ready for use in 2015 and five more experimental vaccines would start being tested in March. (Oct. 24) Video provided by AP
Powered by NewsLook.com
Doctor in NYC Quarantined With Ebola

Doctor in NYC Quarantined With Ebola

AP (Oct. 24, 2014) An emergency room doctor who recently returned to the city after treating Ebola patients in West Africa has tested positive for the virus. He's quarantined in a hospital. (Oct. 24) Video provided by AP
Powered by NewsLook.com

Search ScienceDaily

Number of stories in archives: 140,361

Find with keyword(s):
Enter a keyword or phrase to search ScienceDaily for related topics and research stories.

Save/Print:
Share:

Breaking News:

Strange & Offbeat Stories


Health & Medicine

Mind & Brain

Living & Well

In Other News

... from NewsDaily.com

Science News

Health News

Environment News

Technology News



Save/Print:
Share:

Free Subscriptions


Get the latest science news with ScienceDaily's free email newsletters, updated daily and weekly. Or view hourly updated newsfeeds in your RSS reader:

Get Social & Mobile


Keep up to date with the latest news from ScienceDaily via social networks and mobile apps:

Have Feedback?


Tell us what you think of ScienceDaily -- we welcome both positive and negative comments. Have any problems using the site? Questions?
Mobile: iPhone Android Web
Follow: Facebook Twitter Google+
Subscribe: RSS Feeds Email Newsletters
Latest Headlines Health & Medicine Mind & Brain Space & Time Matter & Energy Computers & Math Plants & Animals Earth & Climate Fossils & Ruins